Literature DB >> 23864165

Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.

W Caleb Rutledge1, Jun Kong, Jingjing Gao, David A Gutman, Lee A D Cooper, Christina Appin, Yuna Park, Lisa Scarpace, Tom Mikkelsen, Mark L Cohen, Kenneth D Aldape, Roger E McLendon, Norman L Lehman, C Ryan Miller, Matthew J Schniederjan, Cameron W Brennan, Joel H Saltz, Carlos S Moreno, Daniel J Brat.   

Abstract

PURPOSE: Tumor-infiltrating lymphocytes (TIL) have prognostic significance in many cancers, yet their roles in glioblastoma have not been fully defined. We hypothesized that TILs in glioblastoma are associated with molecular alterations, histologies, and survival. EXPERIMENTAL
DESIGN: We used data from The Cancer Genome Atlas (TCGA) to investigate molecular, histologic, and clinical correlates of TILs in glioblastomas. Lymphocytes were categorized as absent, present, or abundant in histopathologic images from 171 TCGA glioblastomas. Associations were examined between lymphocytes and histologic features, mutations, copy number alterations, CpG island methylator phenotype, transcriptional class, and survival. We validated histologic findings using CD3G gene expression.
RESULTS: We found a positive correlation between TILs and glioblastomas with gemistocytes, sarcomatous cells, epithelioid cells, and giant cells. Lymphocytes were enriched in the mesenchymal transcriptional class and strongly associated with mutations in NF1 and RB1. These mutations are frequent in the mesenchymal class and characteristic of gemistocytic, sarcomatous, epithelioid, and giant cell histologies. Conversely, TILs were rare in glioblastomas with small cells and oligodendroglioma components. Lymphocytes were depleted in the classical transcriptional class and in EGF receptor (EGFR)-amplified and homozygous PTEN-deleted glioblastomas. These alterations are characteristic of glioblastomas with small cells and glioblastomas of the classical transcriptional class. No association with survival was shown.
CONCLUSIONS: TILs were enriched in glioblastomas of the mesenchymal class, strongly associated with mutations in NF1 and RB1 and typical of histologies characterized by these mutations. Conversely, TILs were depleted in the classical class, EGFR-amplified, and homozygous PTEN-deleted tumors and rare in histologies characterized by these alterations. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864165      PMCID: PMC3865611          DOI: 10.1158/1078-0432.CCR-13-0551

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  How dense, how intense? Role of tumour-infiltrating lymphocytes across colorectal cancer stages. Re: Nosho et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-366.

Authors:  Luigi Laghi; Paolo Bianchi; Fabio Grizzi; Alberto Malesci
Journal:  J Pathol       Date:  2011-08-08       Impact factor: 7.996

2.  The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.

Authors:  Lee A D Cooper; David A Gutman; Candace Chisolm; Christina Appin; Jun Kong; Yuan Rong; Tahsin Kurc; Erwin G Van Meir; Joel H Saltz; Carlos S Moreno; Daniel J Brat
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

3.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas.

Authors:  H Safdari; F H Hochberg; E P Richardson
Journal:  Surg Neurol       Date:  1985-03

5.  Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.

Authors:  Brian P Pollack; Bishu Sapkota; Todd V Cartee
Journal:  Clin Cancer Res       Date:  2011-05-17       Impact factor: 12.531

6.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

8.  Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis.

Authors:  Anand G Menon; Connie M Janssen-van Rhijn; Hans Morreau; Hein Putter; Rob A E M Tollenaar; Cornelis J H van de Velde; Gert Jan Fleuren; Peter J K Kuppen
Journal:  Lab Invest       Date:  2004-04       Impact factor: 5.662

9.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

View more
  95 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.

Authors:  Hideki Murata; Koji Yoshimoto; Ryusuke Hatae; Yojiro Akagi; Masahiro Mizoguchi; Nobuhiro Hata; Daisuke Kuga; Akira Nakamizo; Toshiyuki Amano; Tetsuro Sayama; Koji Iihara
Journal:  J Neurooncol       Date:  2015-08-14       Impact factor: 4.130

3.  Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma.

Authors:  Chen Zhu; Cunyi Zou; Gefei Guan; Qing Guo; Zihao Yan; Tianqi Liu; Shuai Shen; Xiaoyan Xu; Chen Chen; Zhiguo Lin; Wen Cheng; Anhua Wu
Journal:  Oncoimmunology       Date:  2019-06-12       Impact factor: 8.110

4.  Tumor-infiltrating lymphocytes (TILs) from patients with glioma.

Authors:  Zhenjiang Liu; Qingda Meng; Jiri Bartek; Thomas Poiret; Oscar Persson; Lalit Rane; Elena Rangelova; Christopher Illies; Inti Harvey Peredo; Xiaohua Luo; Martin Vijayakumar Rao; Rebecca Axelsson Robertson; Ernest Dodoo; Markus Maeurer
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

5.  Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.

Authors:  Norman L Lehman; Eyas M Hattab; Bret C Mobley; Aisulu Usubalieva; Matthew J Schniederjan; Roger E McLendon; Werner Paulus; Elisabeth J Rushing; Maria-Magdalena Georgescu; Marta Couce; Mohanpal S Dulai; Mark L Cohen; Christopher R Pierson; Jack M Raisanen; Sarah E Martin; Trang D Lehman; Eric S Lipp; Jose M Bonnin; Mousa A Al-Abbadi; Kara Kenworthy; Kevin Zhao; Nehad Mohamed; Guojuan Zhang; Weiqiang Zhao
Journal:  Neuro Oncol       Date:  2016-07-14       Impact factor: 12.300

6.  Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.

Authors:  David K Meyerholz; Georgina K Ofori-Amanfo; Mariah R Leidinger; J Adam Goeken; Rajesh Khanna; Jessica C Sieren; Benjamin W Darbro; Dawn E Quelle; Jill M Weimer
Journal:  J Histochem Cytochem       Date:  2017-08-28       Impact factor: 2.479

Review 7.  Effective effectors: How T cells access and infiltrate the central nervous system.

Authors:  Kendra L Congdon; Luis A Sanchez-Perez; John H Sampson
Journal:  Pharmacol Ther       Date:  2018-12-14       Impact factor: 12.310

8.  Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.

Authors:  Ichiyo Shibahara; Mitsuto Hanihara; Takashi Watanabe; Mitsuru Dan; Sumito Sato; Hiroki Kuroda; Akinori Inamura; Madoka Inukai; Atsuko Hara; Yoshie Yasui; Toshihiro Kumabe
Journal:  J Neurooncol       Date:  2018-02-21       Impact factor: 4.130

9.  Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.

Authors:  Hirokazu Sadahiro; Kyung-Don Kang; Justin T Gibson; Mutsuko Minata; Hai Yu; Junfeng Shi; Rishi Chhipa; Zhihong Chen; Songjian Lu; Yannick Simoni; Takuya Furuta; Hemragul Sabit; Suojun Zhang; Soniya Bastola; Shinobu Yamaguchi; Hebaallah Alsheikh; Svetlana Komarova; Jun Wang; Sung-Hak Kim; Dolores Hambardzumyan; Xinghua Lu; Evan W Newell; Biplab DasGupta; Mitsutoshi Nakada; L James Lee; Burt Nabors; Lyse A Norian; Ichiro Nakano
Journal:  Cancer Res       Date:  2018-03-12       Impact factor: 12.701

Review 10.  The Dynamics of Interactions Among Immune and Glioblastoma Cells.

Authors:  Katalin Eder; Bernadette Kalman
Journal:  Neuromolecular Med       Date:  2015-07-30       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.